Effects of the components of hormone therapy on matrix metalloproteinases in breast-cancer cells: an in vitro study.
A combination of E and progestogens significantly increased matrix metalloproteinase (MMP)-2 in both T47D cells (E(2)-medroxyprogesteroneacetate [MPA] and E(2)-P) and MCF-7 cells (E(2)-MPA, E(2)-P, and equilin-MPA). All combinations resulted in higher MMP-9 levels in MCF-7 cells, but higher MMP-9 levels resulted only with equilin-norethinderone in T47D cells.
Abdallah
Maher A
MA
Abdullah
Huda I
HI
Kang
Steven
S
Taylor
Douglas D
DD
Nakajima
Steven T
ST
Gercel-Taylor
Cicek
C
D001943:Breast Neoplasms / Q000201:enzymology*; D045744:Cell Line, Tumor; D004857:Equilin / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology; D005260:Female; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology; D009640:Norethindrone / Q000031:analogs & derivatives / Q000494:pharmacology; D000077563:Norethindrone Acetate; D011374:Progesterone / Q000494:pharmacology
D004966:Estrogens, Conjugated (USP); D004857:Equilin; D011374:Progesterone; D004958:Estradiol; D000077563:Norethindrone Acetate; D017258:Medroxyprogesterone Acetate; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D009640:Norethindrone